Skip to content
Peptide research

Catestatin

Also known as CST · Chromogranin A Fragment
Category
Cardiovascular
Administration routes
Injectable
Regulatory status
Not FDA-approved

A chromogranin A fragment from nerve endings and adrenal glands, marketed for blood pressure, heart, and gut support. Evidence is mostly animal and mechanistic; in humans it is studied mainly as a heart failure biomarker, while hypertension and colitis claims stay low confidence. Therapeutic safety remains unestablished, and suppressing adrenaline raises concern for hypotension and allergy. Not approved, and available products are unregulated.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Catestatin is a naturally occurring 21-amino-acid peptide discovered in 1997 that is released alongside adrenaline and noradrenaline from the adrenal glands and sympathetic nerve endings. It acts as a built-in "brake" on your stress response — when stress hormones are released, catestatin is released with them and signals the body to stop producing more, creating a natural negative feedback loop. Beyond this core role, it has been found to regulate blood pressure, improve insulin sensitivity, fight infections, and reduce inflammation.

How it works in the body

A fragment of chromogranin A released from nerve endings and adrenal glands. It blocks nicotinic acetylcholine receptors on adrenal chromaffin cells, reducing the release of catecholamines (adrenaline/noradrenaline). This lowers blood pressure and heart rate while also having direct antimicrobial and anti-inflammatory effects.

Research overview

Catestatin works by blocking nicotinic receptors on adrenaline-producing cells, preventing excessive stress hormone release. This creates an elegant self-regulating system: when your body releases adrenaline, it simultaneously releases catestatin to prevent an overreaction. Beyond stress regulation, animal studies show it lowers blood pressure through blood vessel dilation, protects the heart from damage during blood flow interruptions, improves insulin sensitivity and fat metabolism, reduces intestinal inflammation in colitis models, and even acts as a natural antimicrobial on the skin. In humans, catestatin levels are notably lower in people with hypertension — and importantly, also in their still-healthy children — suggesting that low catestatin may contribute to developing high blood pressure. About 305 publications exist on PubMed. Human data also include local-infusion experiments, but no therapeutic trials of catestatin as a treatment have been conducted yet, so its potential as an administered drug remains theoretical.

Who researches Catestatin?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

Important considerations for

  • Those with Severe hypotension

    High

    Catestatin inhibits catecholamine release and causes vasodilation. May dangerously lower BP in hypotensive patients.

  • Those with Pheochromocytoma or catecholamine-secreting tumors

    Moderate

    Catestatin modulates catecholamine dynamics. Unpredictable effects on catecholamine-secreting tumors.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data. Affects catecholamine and cardiovascular regulation.

Safety & interactions

Do not use if

  • Severe hypotension

    High

    Catestatin inhibits catecholamine release and causes vasodilation. May dangerously lower BP in hypotensive patients.

  • Pheochromocytoma or catecholamine-secreting tumors

    Moderate

    Catestatin modulates catecholamine dynamics. Unpredictable effects on catecholamine-secreting tumors.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data. Affects catecholamine and cardiovascular regulation.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • Therapeutic safety remains unestablished

    High

    Fung et al., 2010, PMID 20662728; limited experimental exposure.

  • Hypotension and cardiovascular depression

    Moderate

    Rodent/isolated-heart studies of catestatin cardiac inotropism and lusitropism; endothelial PI3K-eNOS antiadrenergic mechanism studies

  • Histamine release and allergic-type reactions

    Moderate

    Aung et al., human mast cell migration, degranulation and mediator release in response to catestatin (Immunology 2011). MRGPRX2 dependence: mechanistically supported, primary citation unverified.

  • Immune modulation with unpredictable consequences

    Moderate

    Rabbi et al., Biochem Pharmacol 2014; Aung et al. human mast cell study; general reviews of catestatin as a multifunctional peptide

  • Sympathetic rebound or autonomic instability

    Theoretical

    Rodent studies of catestatin sympathoinhibition and baroreflex/chemoreflex attenuation; human variant-carrier baroreceptor slope data (Rao et al., Circulation 2007).

  • Research-grade product quality and contamination

    High

    Regulatory status: no FDA-approved catestatin product and no USP monograph; general research-chemical peptide quality literature

  • Variant-specific differential effects

    Moderate

    Rao et al., Circulation 2007 (variant potency and human autonomic phenotypes); rodent studies of human catestatin variants in infarct size and hypertension models

Interaction summary(8)

Rated by direction with this peptide

  • Antihypertensive drugs (ACE inhibitors, ARBs, calcium channel blockers, diuretics, alpha-blockers)

    CautionModerate

    Catestatin's core demonstrated action is sympathoinhibitory and blood-pressure-lowering in animals, so adding it to an established antihypertensive regimen plausibly risks additive hypotension, dizziness and syncope, with no human dose guidance to titrate against. The additive effect is inferred from animal pharmacology; no human co-administration has ever occurred.

    Rodent BP and sympathoinhibition studies; reviews of catestatin cardiovascular pharmacology

  • Beta-blockers and other negative inotropes

    CautionModerate

    Catestatin depresses cardiac inotropism and lusitropism through an endothelial PI3K/eNOS/cGMP antiadrenergic pathway while also reducing catecholamine release upstream, so combining it with beta-blockade could compound bradycardia and reduced contractility, particularly in heart failure. Basis is isolated-heart and rodent work only; severity kept Moderate because the clinical consequence in a decompensated patient would be serious even though the interaction is unproven in humans.

    Isolated-heart studies of catestatin inotropism/lusitropism; endothelial PI3K-eNOS antiadrenergic mechanism

  • Nicotine, varenicline and other nicotinic acetylcholine receptor agonists

    CautionLow

    Catestatin is a non-competitive nicotinic cholinergic antagonist at chromaffin and neuronal receptors, so it should pharmacologically oppose nicotinic agonists and partial agonists - a mutual-blunting interaction rather than a toxicity, but one that makes both agents' effects unpredictable.

    Established non-competitive nicotinic antagonism of catestatin at chromaffin-cell receptors (Mahata/O'Connor line of work)

  • Ganglionic blockers and nicotinic antagonists (e.g. hexamethonium-class agents, high-dose neuromuscular blockers)

    CautionTheoretical

    The additive effect here is harm (deeper sympathetic blockade and orthostatic hypotension), and labelling it synergistic reads as a benefit in a safety table. Both agents act at nicotinic receptors to interrupt autonomic ganglionic transmission, so co-exposure would be expected to compound the blockade. Purely mechanistic inference; not tested in any species.

    Mechanistic inference from catestatin's nicotinic antagonism; no direct co-administration study identified

  • MRGPRX2-activating drugs (vancomycin, fluoroquinolones, neuromuscular blocking agents, icatibant, some opioids)

    CautionLow

    Severity reduced from Moderate to Low. Catestatin does trigger human mast-cell degranulation and histamine release in vitro, and the listed drugs are established MRGPRX2 activators, so overlapping exposure could compound flushing, urticaria and pseudo-allergic reactions. But the shared-receptor step for catestatin specifically rests on the unverified 2026 citation plus mechanistic plausibility, and no case of such an interaction has been observed, so a Moderate rating overstates the human evidence.

    Aung et al., human mast cell degranulation by catestatin; established MRGPRX2 pharmacology of vancomycin/fluoroquinolones/NMBAs. Catestatin-MRGPRX2 link: probable, primary citation unverified.

  • Insulin and insulin-sensitizing agents (metformin, GLP-1 receptor agonists, sulfonylureas)

    CautionTheoretical

    Catestatin improves insulin sensitivity and suppresses hepatic glucose production in obese mice, so in principle it could add to glucose-lowering therapy and increase hypoglycemia risk. Never observed in a human on either agent; rated Theoretical because the hypoglycemia consequence is actionable even on animal evidence alone.

    Ying et al., Diabetes 2018;67:841; rodent ER-stress metabolic studies

  • Proton pump inhibitors and other chromogranin A-raising drugs (H2 blockers, somatostatin analogues)

    CautionLow

    Severity reduced from Moderate to Low. This is an assay-interpretation confound, not a pharmacodynamic drug interaction, and it carries no direct patient harm from co-exposure. PPIs markedly elevate circulating chromogranin A - the precursor from which catestatin is cleaved - which can confound interpretation of CgA or catestatin measurements used for heart-failure prognostication or neuroendocrine-tumor workup. CgA elevation by acid suppression is well established; the downstream effect on catestatin assays specifically is inferred.

    Established chromogranin A assay confounding by acid suppression; catestatin as a CgA-derived analyte

  • Mast cell stabilizers and H1 antihistamines

    ProtectiveLow

    Because catestatin's most likely acute adverse effect in humans is mast-cell degranulation, antihistamines and mast-cell stabilizers would be expected to blunt flushing, itch and wheal responses - protective against the peptide's side effects, though in mice the antimicrobial wound-healing effect required mast cells, so blunting them may also blunt that unproven benefit. The reasoning is mechanistic, not tested.

    Aung et al., human mast cell response to catestatin; standard antihistamine/mast-cell-stabilizer pharmacology

Known risks(7)

  • Therapeutic safety remains unestablished

    High

    Limited experimental human exposure does not establish therapeutic safety. The therapeutic index, maximum tolerated dose, and adverse effect profile in humans are entirely unknown.

  • Hypotension and cardiovascular depression

    High

    Catestatin lowers blood pressure through vasodilation and catecholamine release inhibition. Exogenous administration, particularly in individuals already on antihypertensive medications, could theoretically cause dangerous hypotension. In animal studies, catestatin reduces both blood pressure and cardiac contractility (negative inotropic and lusitropic effects).

  • Histamine release and allergic-type reactions

    Moderate

    Catestatin's vasodilatory mechanism involves histamine release and H1 receptor activation. It also induces mast cell migration, degranulation, and cytokine production. These properties could trigger histamine-mediated adverse reactions including flushing, urticaria, bronchoconstriction, or anaphylactoid responses.

  • Immune modulation with unpredictable consequences

    Moderate

    Catestatin suppresses M1 macrophage function and proinflammatory cytokine release. While beneficial in inflammatory conditions, this immunosuppression could impair host defense against infections or alter immune surveillance. The antimicrobial peptide activity may also select for antimicrobial-resistant gut bacteria (Tsai et al. 2022, ISME Journal).

  • Sympathetic rebound or autonomic instability

    Moderate

    By inhibiting catecholamine release, exogenous catestatin could disrupt the finely tuned sympathetic-parasympathetic balance. Withdrawal or discontinuation might theoretically cause rebound sympathetic hyperactivity, similar to beta-blocker withdrawal. No data exists on this risk.

  • Research-grade product quality and contamination

    High

    All available catestatin is research-grade, intended for laboratory use only. Research peptides may contain synthesis impurities, endotoxins, or degradation products that pose serious risks if injected. There is no pharmaceutical-grade catestatin suitable for human administration.

  • Variant-specific differential effects

    Naturally occurring human catestatin variants (Gly364Ser, Pro370Leu, Arg374Gln) show markedly different biological potencies. Synthetic catestatin based on the wild-type sequence may have differential effects depending on the recipient's genotype, and one variant paradoxically enhanced infarct size in ex vivo heart models.

Drug interactions(6)

  • Antihypertensive medications (ACE inhibitors, ARBs, calcium channel blockers, diuretics)

    Theoretical additive hypotensive effect. Catestatin lowers blood pressure through catecholamine release inhibition and vasodilation. Combined use with antihypertensives could potentiate blood pressure reduction beyond intended levels, risking symptomatic hypotension.

  • Beta-adrenergic blockers

    Synergistic sympatholytic effect. Both catestatin and beta-blockers reduce sympathetic drive, though by different mechanisms (catestatin inhibits catecholamine release upstream; beta-blockers block receptors downstream). Combined use could cause excessive bradycardia, hypotension, or heart block. Animal studies show catestatin attenuates isoproterenol effects centrally.

  • Nicotinic receptor agonists (nicotine, varenicline)

    Pharmacodynamic antagonism. Catestatin is a noncompetitive nicotinic cholinergic antagonist. It could reduce the efficacy of nicotinic agonists used for smoking cessation (varenicline) or the effects of nicotine itself. High-dose nicotine fails to overcome catestatin's inhibition in vitro.

  • Antihistamines (H1 blockers)

    May attenuate catestatin's vasodilatory effects. Catestatin's blood pressure-lowering mechanism involves histamine release and H1 receptor activation. H1 antihistamines could block this pathway, potentially reducing catestatin's cardiovascular effects.

  • Insulin and oral hypoglycemics (metformin, sulfonylureas)

    Theoretical additive glucose-lowering effect. Catestatin improves insulin sensitivity, suppresses hepatic glucose production, and reduces plasma insulin in animal models. Combined use with diabetes medications could theoretically enhance hypoglycemia risk.

  • Immunosuppressants (corticosteroids, calcineurin inhibitors, biologics)

    Theoretical additive immunosuppression. Catestatin suppresses M1 macrophage activation, reduces proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha), and modulates immune cell function. Combined use with immunosuppressive drugs could increase infection susceptibility.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
305
Human Studies
25

Therapeutic evidence remains predominantly preclinical, from in vitro cell culture and in vivo animal (primarily mouse) studies. Human research includes observational biomarker studies, population genetics, and controlled local-infusion experiments. The CATSTAT-HF study (NCT03389386), the largest dedicated clinical study, measured endogenous catestatin in 90 acutely decompensated heart failure patients. Population genetics studies in Indian cohorts (approximately 4,000 subjects) linked catestatin variants to hypertension risk. These findings do not establish clinical treatment benefit. The preclinical evidence across cardiovascular, metabolic, inflammatory, and antimicrobial domains is consistent and compelling, but clinical translation has not yet begun.

Researched for(7)

Rated by confidence in the evidence

  • Blood pressure regulation and antihypertensive effects

    Low

    Animal evidence and limited human vascular experiments; antihypertensive treatment benefit remains unproven.

    Rao et al., Circulation 2007 (Gly364Ser and human autonomic phenotypes); Mahata et al. review of catestatin cardiovascular pharmacology

  • Cardioprotection against ischemia-reperfusion injury

    Low

    Reduced infarct size in rodent heart studies via defined signaling pathways; no human data exist.

    Penna et al., catestatin postconditioning in isolated rat heart; Pflugers Arch 2013 (doi:10.1007/s00424-013-1217-0); rodent studies of human catestatin variants and infarct size.

  • Improved insulin sensitivity and metabolic function

    Low

    Improved insulin sensitivity in mouse and rat studies only; human data are limited to associations.

    Ying et al., Diabetes 2018;67:841 (catestatin, hepatic glucose production and liver macrophage inflammation); rodent ER-stress and GLUT4-trafficking studies

  • Anti-inflammatory effects in colitis and inflammatory bowel disease

    Low

    Reduced colitis severity in two mouse models; human blood levels rise with active inflammation instead.

    Rabbi et al., Biochem Pharmacol 2014 (doi:10.1016/j.bcp.2014.03.003), catestatin and macrophage function in mouse colitis

  • Antimicrobial defense and wound healing

    Low

    In vitro antimicrobial action is established; a single mouse study shows immune-mediated, not direct, wound clearance.

    Direct antimicrobial activity: Radek KA et al., J Invest Dermatol 2008 (catestatin is induced in skin after injury and has direct in vitro bactericidal activity against S. aureus and other pathogens). Wound-clearance claim: Pundir P et al., "The neuroendocrine peptide catestatin promotes clearance of cutaneous Staphylococcus aureus through mast cell Mrgpr activation," Mucosal Immunology 2026, doi:10.1016/j.mucimm.2026.03.003 (also posted as bioRxiv 2025.06.12.659211). This is a single murine MRSA wound-infection study; catestatin's effect on bacterial clearance and healing is mast-cell Mrgprb2-dependent, not direct antimicrobial killing in that model.

  • Cardiovascular biomarker for heart failure prognosis

    Medium

    Multiple human cohort studies link higher blood levels to worse heart failure outcomes and mortality.

    Prospective HFrEF cohorts with ~2-year follow-up; chronic HF mortality cohort (Int J Cardiol, doi:10.1016/j.ijcard.2016.08.315); CATSTAT-HF (NCT03389386, observational)

  • Adipose tissue regulation and anti-obesity effects

    Low

    Reduced fat mass in obese mice; human studies show inconsistent, sometimes opposite, associations.

    Bandyopadhyay et al., mobilization of fat from adipose tissue by catestatin (rodent/ex vivo); Ying et al., Diabetes 2018;67:841

Benefits(7)

  • Blood pressure regulation and antihypertensive effects

    Mahata et al. 1997 (J Clin Invest) — Discovery paper showing catestatin inhibits catecholamine release via nicotinic antagonism, establishing the autocrine feedback loop. Mahapatra 2008 (Cardiovasc Res) — Review establishing catestatin as a novel endogenous regulator of cardiac function and blood pressure. CgA-knockout mice develop severe hypertension rescued by exogenous catestatin (Mahapatra et al. 2005).

  • Cardioprotection against ischemia-reperfusion injury

    Penna et al. 2013 (Pflugers Arch) — Catestatin reduced infarct size in isolated rat hearts via PI3K/Akt, PKC, mitochondrial KATP channels and ROS signaling. Ying et al. 2021 (Hypertension) — Macrophage immunosuppression underlies the cardioprotective effects of catestatin; CST-KO mice show LV hypertrophy and cardiac macrophage infiltration.

  • Improved insulin sensitivity and metabolic function

    Ying et al. 2018 (Diabetes) — Catestatin inhibited obesity-induced macrophage infiltration in liver, suppressed hepatic glucose production, decreased hepatic/plasma lipids and plasma insulin in diet-induced obese mice. Ying et al. 2020 (Comput Struct Biotechnol J) — Catestatin improved insulin sensitivity by attenuating endoplasmic reticulum stress.

  • Anti-inflammatory effects in colitis and inflammatory bowel disease

    Rabbi et al. 2014 (Biochem Pharmacol) — Catestatin decreased macrophage function in two mouse models of experimental colitis (DSS and DNBS), reducing proinflammatory cytokines via STAT3. Rabbi et al. 2017 (Front Immunol) — Catestatin suppressed reactivation of intestinal inflammation via M1 macrophage modulation. Muntjewerff et al. 2018 (Vaccines) — Catestatin enhanced migration, proliferation, and viability of colonic cells.

  • Antimicrobial defense and wound healing

    Radek et al. 2008 (J Invest Dermatol) — Catestatin is a cutaneous antimicrobial peptide expressed in keratinocytes, induced after skin injury, and active against gram-positive and gram-negative bacteria, yeast, and fungi via membrane disruption. Briolat et al. 2005 first reported non-hemolytic antimicrobial effects. Sato et al. 2011 — Catestatin enhances migration and proliferation of human epidermal keratinocytes.

  • Cardiovascular biomarker for heart failure prognosis

    Borovac et al. 2019 (J Clin Med, CATSTAT-HF study) — Catestatin independently correlated with NYHA class, metabolic markers, and echocardiographic parameters in 90 ADHF patients. Wolowiec et al. 2020 (Disease Markers, PMID 33082887) — Catestatin emerged as a new prognostic marker in stable HFrEF patients over 2-year follow-up.

  • Adipose tissue regulation and anti-obesity effects

    Gayen et al. 2009 (J Endocrinol) — Catestatin mobilized fat from adipose tissue through regulation of adrenergic and leptin signaling, promoting lipolysis by blocking alpha-adrenergic receptor signaling and stimulating fatty acid oxidation.

Key studies(5)

  1. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist

    Original research (in vitro / ex vivo)Pheochromocytoma cells, adrenal chromaffin cells, noradrenergic neuritesAcute experiments

    Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ

    Journal of Clinical Investigation

    1997

    Discovery paper. Identified catestatin (bovine CgA344-364) as a potent, dose-dependent (IC50 ~200 nM), reversible inhibitor of nicotinic cholinergic-stimulated catecholamine secretion. Demonstrated noncompetitive nicotinic antagonism via disruption of Na+ and Ca2+ signal transduction. Established the autocrine negative-feedback mechanism for catecholamine release regulation.

  2. Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity

    Original research (preclinical, diet-induced obese mice)Multiple mouse cohorts (HFD model)15 days IP injection (2 mcg/g body weight)

    Ying W, Mahata S, Bandyopadhyay GK, Zhou Z, Wollam J, Vu J, Mayoral R, Chi NW, Webster NJG, Corti A, Mahata SK

    Diabetes

    2018

    Catestatin decreased hepatic and plasma lipids, plasma insulin, gluconeogenic gene expression, and proinflammatory macrophage infiltration in livers of diet-induced obese mice. Increased anti-inflammatory gene expression in macrophages. Established catestatin's metabolic regulatory role beyond cardiovascular effects.

  3. Immunosuppression of Macrophages Underlies the Cardioprotective Effects of CST (Catestatin)

    Original research (preclinical, CST-KO mouse model)CST-knockout and wild-type mice, ischemia-reperfusion modelVarious acute and chronic protocols

    Ying W, Tang K, Avolio E, Schilling JM, Pasqua T, Liu MA, Cheng H, Gao H, Zhang J, Mahata S, Ko MS, Bandyopadhyay G, Das S, Roth DM, Sahoo D, Webster NJG, Sheikh F, Ghosh G, Patel HH, Ghosh P, van den Bogaart G, Mahata SK

    Hypertension

    2021

    CST-knockout mice displayed left ventricular hypertrophy, marked macrophage infiltration of the heart and adrenal gland, elevated proinflammatory cytokines and catecholamines. Ischemic preconditioning-induced cardioprotection was abolished in CST-KO mice. Demonstrated that macrophage immunosuppression is a key mechanism underlying catestatin's cardioprotective effects.

  4. Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study

    Observational clinical study (human biomarker)90 acutely decompensated heart failure patientsCross-sectional at admission, enrolled Jan 2018 - Feb 2019

    Borovac JA, Glavas D, Susilovic Grabovac Z, Supe Domic D, D'Amario D, Bozic J

    Journal of Clinical Medicine

    2019

    Catestatin levels were significantly higher in ADHF patients with MI history vs without (8.94 vs 4.90 ng/mL, p=0.001). CST independently correlated with NYHA class, waist-to-hip ratio, HbA1c, LDL, non-HDL cholesterol, troponin I, heart rate, and echocardiographic parameters. Established catestatin as a clinically relevant biomarker in heart failure.

  5. Kiranmayi M, Chirasani VR, Allu PKR, Subramanian L, Martelli EE, Sahu BS, Vishnuprabu D, Kumaragurubaran R, Sharma S, Bodhini D, Dixit M, Munirajan AK, Khullar M, Radha V, Mohan V, Mullasari AS, Naga Prasad SV, Senapati S, Mahapatra NR

    Hypertension

    2016

    The naturally occurring CST-Gly364Ser variant was associated with increased hypertension risk (odds ratios: 1.483 and 2.951 in two populations). 364Ser carriers displayed elevated systolic BP (up to ~8 mmHg) and diastolic BP (up to ~6 mmHg). The mechanism involves reduced endothelial NO release by the Ser variant compared to wild-type catestatin.

Regulation & availability

Why researchers look at it

Human studies found catestatin levels are notably lower in people with hypertension — and critically, also in their still-normotensive children — suggesting the deficiency may be causal rather than consequential. Population genetics studies in ~4,000 subjects have linked catestatin variants to hypertension risk, and roughly 305 publications document its role as a natural brake on the stress response. Despite this, no human has ever received catestatin as a therapeutic agent and no pharmaceutical development program exists.

FDA status
Not FDA-approved for any indication. Catestatin has not been the subject of any New Drug Application (NDA), Biologics License Application (BLA), or Investigational New Drug (IND) application. No pharmaceutical company has initiated interventional clinical trials of exogenous catestatin for therapeutic purposes. Human experimental administration exists; therapeutic efficacy remains unestablished. It does not appear on the FDA's list of bulk drug substances that may present significant safety risks for compounding (because it has never been compounded for clinical use). It is not listed on FDA's 503A or 503B interim bulks lists. The absence of IND activity reflects the early-stage nature of catestatin therapeutic research rather than any specific FDA enforcement action.
WADA status
Not explicitly named on the WADA Prohibited List, but likely prohibited under S0 (Non-Approved Substances). Section S0 covers 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use.' Since catestatin has no FDA or any regulatory authority approval for human therapeutic use, exogenous administration would fall under S0. Additionally, as a peptide with cardiovascular and metabolic effects, it could be argued to fall under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) depending on interpretation. Athletes should consider catestatin prohibited and consult their national anti-doping organization before any use.
Prescribability
Not prescribable as an FDA-approved medication; catestatin has no FDA approval for any indication. It has never been the subject of an Investigational New Drug (IND) application for therapeutic use in humans. No pharmaceutical company has advanced catestatin into human interventional clinical trials. Human experimental administration exists, but no established therapeutic prescription pathway was identified.
Availability
Catestatin is NOT available as a therapeutic pharmaceutical product for human use.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(13)

  1. 1997-09
    Catestatin discovered by Mahata, O'Connor et al. at UC San Diego. Published in Journal of Clinical Investigation (PMID 9294131). Identified as catecholamine release-inhibitory fragment of chromogranin A (bovine CgA344-364) and noncompetitive nicotinic antagonist.
  2. 2002-06
    O'Connor characterizes the catestatin region of chromogranin A in Annals of the New York Academy of Sciences. Human catestatin sequence (CgA352-372) established.
  3. 2005
    Antimicrobial activity of catestatin first reported by Briolat et al. Non-hemolytic effects against bacteria, fungi, and yeast demonstrated. Hypertension from chromogranin A knockout rescued by exogenous catestatin (Mahapatra et al.).
  4. 2007-04
    Human catestatin variants (Gly364Ser, Pro370Leu, Arg374Gln) characterized for differential nicotinic receptor responses and autonomic effects. Gly364Ser linked to altered hypertension risk (O'Connor et al., Circulation).
  5. 2008-06
    Radek et al. publish in J Invest Dermatol showing catestatin is a cutaneous antimicrobial peptide expressed in keratinocytes and induced after skin injury.
  6. 2010-06
    Mahata et al. publish comprehensive review 'Catestatin: a multifunctional peptide from chromogranin A' in Regulatory Peptides (PMID 20116404), establishing the multi-system significance of catestatin.
  7. 2016-08
    Kiranmayi et al. publish human population genetics study in Hypertension linking Gly364Ser variant to hypertension risk in ~4000 Indian subjects via endothelial NO pathway (PMID 27324226).
  8. 2018-01
    CATSTAT-HF clinical study (NCT03389386) begins enrollment at University Hospital of Split, Croatia. First dedicated clinical trial measuring catestatin as a biomarker in acutely decompensated heart failure.
  9. 2018-05
    Ying et al. publish landmark metabolic study in Diabetes (PMID 29432123) showing catestatin inhibits obesity-induced hepatic macrophage infiltration and improves insulin sensitivity.
  10. 2021-05
    Ying et al. publish cardioprotection study in Hypertension (PMID 33826401) demonstrating CST-KO mouse cardiac phenotype and macrophage-mediated cardioprotective mechanism.
  11. 2022-05
    Zalewska et al. publish comprehensive review of catestatin's role in cardiovascular system and metabolic disorders in Frontiers in Cardiovascular Medicine (PMID 35665253). Literature search yields 235 catestatin publications.
  12. 2022-10
    Gata-Simion et al. publish assessment of plasma catestatin in COVID-19 in Frontiers in Immunology, revealing elevated catestatin in hospitalized COVID-19 patients with impact on morbidity-mortality.
  13. 2025-03
    Review on 'Catestatin in Cardiovascular Diseases' published in Int J Mol Sci. Catestatin PubMed publications reach ~305. Research continues expanding into ankylosing spondylitis, gestational diabetes, Hashimoto's thyroiditis, and other conditions. No IND or therapeutic trials initiated.

Sources & FAQs

Research sources(25)

  1. Mahata et al. 1997 — Discovery of catestatin, autocrine catecholamine feedback
  2. Mahata et al. 2010 — Catestatin: a multifunctional peptide from chromogranin A (review)
  3. Mahapatra 2008 — Catestatin regulates cardiac function and blood pressure (review)
  4. Ying et al. 2018 — Catestatin inhibits obesity-induced macrophage infiltration, insulin sensitivity
  5. Ying et al. 2020 — Catestatin improves insulin sensitivity via ER stress attenuation
  6. Ying et al. 2021 — Macrophage immunosuppression underlies catestatin cardioprotection
  7. Kiranmayi et al. 2016 — Gly364Ser variant alters BP and hypertension risk (human)
  8. O'Connor et al. 2007 — Catestatin review in Circulation
  9. Borovac et al. 2019 — CATSTAT-HF study, catestatin in acute heart failure
  10. Borovac et al. 2020 — Catestatin as prognostic marker in HFrEF (2-year follow-up)
  11. Rabbi et al. 2014 — Catestatin decreases macrophage function in colitis models
  12. Rabbi et al. 2017 — Catestatin suppresses colitis reactivation via M1 macrophages
  13. Radek et al. 2008 — Catestatin is a cutaneous antimicrobial, induced after injury
  14. Jati et al. 2023 — Catestatin antimicrobial functions and potential therapeutics (review)
  15. Zalewska et al. 2022 — Role of catestatin in cardiovascular system and metabolic disorders (review)
  16. Angelone et al. 2008 — Catestatin as cardiac inotropic/lusitropic modulator
  17. Gayen et al. 2009 — Catestatin mobilizes fat via adrenergic and leptin signaling
  18. Biswas et al. 2009 — Chromogranin A-null model, autonomic and cardiovascular instability
  19. Bozic et al. 2021 — Catestatin as biomarker of cardiovascular diseases (review)
  20. Derella et al. 2022 — Catestatin and arterial stiffness in primary hypertension
  21. Brnic et al. 2020 — Catestatin and arterial stiffness in IBD patients
  22. Gata-Simion et al. 2022 — Catestatin in COVID-19, inflammatory activity and prognosis
  23. CATSTAT-HF clinical trial registration
  24. WADA 2026 Prohibited List
  25. Mahata et al. 2007 — Catestatin human variants and nicotinic cholinergic responses

Frequently asked questions(5)

What is the difference between catestatin and chromogranin A?

Chromogranin A (CgA) is a large 439-amino-acid prohormone protein stored in secretory granules of neuroendocrine cells, adrenal chromaffin cells, and neurons. Catestatin is one of several bioactive peptide fragments produced by proteolytic cleavage of CgA (specifically human CgA residues 352-372). Other CgA-derived peptides include vasostatin-1, pancreastatin, and serpinin, each with distinct biological functions. CgA is the precursor; catestatin is one of its functional products.

Has catestatin been tested as a drug in humans?

No. As of 2026, no published clinical trial has administered exogenous catestatin to humans for therapeutic purposes. Human experimental administration has been published, but clinical treatment benefit remains unestablished. Observational studies have measured naturally occurring catestatin levels in blood as a biomarker for cardiovascular disease, metabolic syndrome, heart failure, or COVID-19 severity. CATSTAT-HF (NCT03389386), the best-known clinical study, was observational: it measured endogenous catestatin rather than administering it. Therapeutic catestatin research remains entirely in the preclinical (cell culture and animal) stage.

Why are catestatin levels low in hypertensive patients?

In hypertension, chromogranin A (CgA) levels are elevated but its processing to catestatin is impaired, resulting in a paradox of high CgA but low catestatin. Since catestatin acts as a natural 'brake' on catecholamine release and blood pressure, its deficiency may contribute to sympathetic overactivity and sustained hypertension. Notably, low catestatin is observed even in still-normotensive offspring of hypertensive parents, suggesting it may be an early predisposing factor rather than a consequence of established hypertension.

Is catestatin the same as a beta-blocker?

No, though both reduce sympathetic drive. Beta-blockers directly block beta-adrenergic receptors on target organs (heart, blood vessels). Catestatin acts upstream by inhibiting catecholamine release at the source — the adrenal medulla and sympathetic nerve terminals — through noncompetitive nicotinic cholinergic antagonism. Additionally, catestatin has anti-inflammatory, metabolic, and antimicrobial properties that beta-blockers lack. They are mechanistically distinct.

Can catestatin be used as a supplement or for self-injection?

Self-administration would be highly inadvisable given the lack of established therapeutic safety.